INS and type 2 diabetes mellitus: In the trial by Pratley et al. 75, vildagliptin monotherapy yielded consistently robust improvement in beta-cell function, measured not only by HOMA-B based on fasting glucose and insulin but also by meal test-derived measures, across a broad spectrum of drug-naive patients with T2DM.